Eisai seeks TGA reconsideration of lecanemab Alzheimer's drug rejection due to safety concerns.

Eisai, a Japanese pharmaceutical firm, plans to ask Australia's Therapeutic Goods Administration (TGA) to reconsider its rejection of lecanemab, an Alzheimer's treatment already approved in several countries, including the U.S. The TGA cited safety concerns over potential brain swelling and bleeding. While the drug has shown promise in slowing cognitive decline, its high cost and risks have sparked significant debate on its effectiveness and safety.

October 16, 2024
8 Articles